Hostname: page-component-5cf477f64f-54txb Total loading time: 0 Render date: 2025-04-02T13:46:48.668Z Has data issue: false hasContentIssue false
  • English
  • Français

Skin and Environmental Contamination With Vancomycin-Resistant Enterococci in Patients Receiving Oral Metronidazole or Oral Vancomycin Treatment for Clostridium difficile–Associated Disease

Published online by Cambridge University Press:  02 January 2015

Ajay K. Sethi ,
Wafa N. Al-Nassir ,
Michelle M. Nerandzic  and
Curtis J. Donskey
Ajay K. Sethi
Affiliation:
Departments of Epidemiology and Biostatistics, Cleveland, Ohio
Wafa N. Al-Nassir
Affiliation:
Infectious Diseases, Cleveland, Ohio
Michelle M. Nerandzic
Affiliation:
University Hospitals of Cleveland, Case Western Reserve University School of Medicine, and the Research Service, Cleveland, Ohio
Curtis J. Donskey*
Affiliation:
Geriatric Research Education and Clinical Center, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio
*
Geriatric Research Education and Clinical Center, Cleveland VA Medical Center, 10701 East Blvd., Cleveland, OH 44106 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background.

Oral metronidazole has been recommended for treatment of mild-to-moderate Clostridium difficile–associated disease (CDAD), in part because of concern that use of vancomycin may be more likely to promote colonization and transmission of vancomycin-resistant enterococci (VRE). The objective of our study was to compare the frequency of skin and environmental VRE contamination associated with metronidazole treatment for CDAD with such frequency associated with vancomycin treatment for CDAD.

Design.

Prospective, observational study. This study was performed at the Cleveland Veterans Affairs Medical Center (Cleveland, OH). For patients with CDAD who had concurrent VRE colonization, stool, skin, and environmental samples were cultured for VRE before, during, and up to 3 weeks after therapy with metronidazole or vancomycin. The proportions of skin and environmental contamination were compared before and after resolution of diarrhea and during treatment with metronidazole or vancomycin.

Results.

Of the 34 patients, 17 were treated with vancomycin and 17 were treated with metronidazole. The proportion of environmental cultures that were positive for VRE was significantly higher during resolution of diarrhea than it was after resolution of diarrhea (38% vs 28%; P = .025), whereas the proportion of skin cultures positive was not different during and after resolution of diarrhea (78% vs 71%; P = .60). There were no differences between patients who received metronidazole and patients who received vancomycin in the proportions of skin culture results (73% vs 77%; P = .80) or environmental culture results (37% vs 32%; P = .359) that were positive for VRE. Eleven patients (32%) had chronic fecal incontinence, and 28 (82%) had incontinence at least once during their CDAD episode.

Conclusions.

In VRE-colonized patients with CDAD who experienced frequent fecal incontinence, skin and environmental VRE contamination was common during and after resolution of diarrhea. The frequency of VRE contamination was similar between patients treated with metronidazole and patients treated with vancomycin.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 1 , January 2009 , pp. 13 - 17
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Gerding, DN, Johnson, S, Peterson, LR, Mulligan, ME, Silva, J. Clostridium difficile–associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459–477.Google Scholar
2.Gerding, DN. Metronidazole for Clostridium difficile–associated disease: is it okay for Mom? Clin Infect Dis 2005;40:1598–1600.Google Scholar
3.Al-Nassir, WN, Sethi, AK, Li, Y, Pultz, MJ, Riggs, MM, Donskey, CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile–associated disease. Antimicrob Agents Chemother 2008;52:2403–2406.Google Scholar
4.Edlund, C, Barkholt, L, Olsson-Liljequist, B, Nord, CE. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 1997;25:729–732.CrossRefGoogle ScholarPubMed
5.Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HIC-PAC). Am J Infect Control 1995;23:87–94.CrossRefGoogle Scholar
6.Edmond, MB, Ober, JF, Weinbaum, DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126–1133.CrossRefGoogle ScholarPubMed
7.Donskey, CJ, Chowdhry, TK, Hecker, MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925–1932.CrossRefGoogle Scholar
8.Mayer, RA, Geha, RC, Helfand, MS, Hoyen, CK, Salata, RA, Donskey, CJ. Role of fecal incontinence in contamination of the environment with vancomycin-resistant enterococci. Am J Infect Control 2003;31:221–115.CrossRefGoogle ScholarPubMed
9.NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. Wayne, PA: NCCLS, 2005:M7.Google Scholar
10.Leber, AL, Hindler, JF, Kato, EO, Bruckner, DA, Pegues, DA. Laboratory-based surveillance for vancomicina-resistant enterococci: utility of screening stool specimens submitted for Clostridium difficile toxin assay. Infect Control Hosp Epidemiol 2001;22:160–164.Google Scholar
11.Boyce, JM, Opal, SM, Chow, JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148–1153.CrossRefGoogle ScholarPubMed
12.Drees, M, Snydman, DR, Schmid, CH, et al. Antibiotic exposure and room contamination among patients colonized with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2008;29:709–715.CrossRefGoogle ScholarPubMed
13.Vernon, MO, Hayden, MK, Trick, WE, Hayes, RA, Blom, DW, Weinstein, RA. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: The effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006;166:306–12.Google Scholar
14.Hayden, MK, Bonten, JM, Blom, DW, Lyle, EA, van de Vijver, D, Weinstein, R. Reduction in acquisition of vancomycin-resistant Enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 2006;42:1552–60.Google Scholar